Fifty 410

Fifty 410 does not publish a maintenance-dose price outside its funnel, which is why it is recorded here but excluded from computed rankings — the methodology explains the unrankable status.

Not fully published Budget from the maintenance dose, not the starter — the teaser-index analysis shows how start-dose pricing distorts annual totals.

Cash-pay If you have commercial coverage, Medicare, or Medicaid, run the indication doors before paying cash anywhere — a covered brand pen at a $25–$50 copay beats every cash program on this site.

On record: Partner pharmacies (Partner network). Whatever name appears on your own label is the one to check — the license-verification guide is a fifteen-minute workflow, and the label-reading guide covers the rest.

States served on record: Availability confirmed at intake. State availability shifts with pharmacy licensure and telehealth rules, so the intake screen is the final word — our fifty-one state guides in the Journal record which programs served each state at last review.

No — the program price is all-inclusive with no separate membership.

Status printed on the record — tirzepatide: unrankable, captured 2026-08-05. The methodology defines each status, the sources page holds the capture ledger, and a dated checkout screenshot from any reader upgrades a status through the corrections desk.

Per plan terms Always screenshot the terms shown at your own checkout; that capture is what governs your plan.